STRIVERDI RESPIMAT (olodaterol hydrochloride)
Striverdi Respimat is a long-acting inhaled medication used for the daily maintenance of patients with chronic obstructive pulmonary disease (COPD). It helps patients with chronic bronchitis and emphysema by providing long-term relief from airflow obstruction. This medication is taken once a day to manage symptoms over time, though it is not used to manage sudden breathing problems or asthma.
How STRIVERDI RESPIMAT Works
This drug works by binding to and activating beta 2-adrenoceptors in the airways, which triggers the production of an enzyme called adenyl cyclase. This process increases levels of cyclic-AMP, which causes the smooth muscle cells in the lungs to relax. This relaxation leads to bronchodilation, helping to open the airways for easier breathing.
Details
- Status
- Prescription
- First Approved
- 2014-07-31
- Patent Cliff
- 2027
- Routes
- INHALATION
- Dosage Forms
- SPRAY, METERED
STRIVERDI RESPIMAT Approval History
What STRIVERDI RESPIMAT Treats
3 indicationsSTRIVERDI RESPIMAT is approved for 3 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chronic Obstructive Pulmonary Disease
- Chronic Bronchitis
- Emphysema
STRIVERDI RESPIMAT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to STRIVERDI RESPIMAT
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
STRIVERDI RESPIMAT FDA Label Details
Indications & Usage
FDA Label (PDF)STRIVERDI RESPIMAT is indicated for the treatment of Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema.
STRIVERDI RESPIMAT Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for STRIVERDI RESPIMAT
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2027
- • 1 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.